Key regions: Australia, Germany, United Kingdom, United States, France
The demand for Immunosuppressants in Jordan has been on the rise in recent years, driven by various factors.
Customer preferences: Patients suffering from autoimmune diseases, organ transplant recipients, and those with other medical conditions that require immunosuppressive therapy are the primary customers for Immunosuppressants in Jordan. The preference for these drugs is influenced by the effectiveness of the treatment in managing the symptoms of the underlying conditions, as well as the availability of alternative therapies.
Trends in the market: The Immunosuppressants market in Jordan has been experiencing steady growth due to the increasing prevalence of autoimmune diseases in the country. Additionally, the rising number of organ transplant procedures being performed in the country has also contributed to the growth of the market. The introduction of new and more effective Immunosuppressants drugs has also been a significant trend in the market, with many patients opting for these newer drugs over traditional therapies.
Local special circumstances: Jordan has a high prevalence of autoimmune diseases, with estimates suggesting that up to 10% of the population may be affected. This has contributed to the growth of the Immunosuppressants market in the country, as more patients require these drugs to manage their conditions. Additionally, Jordan has a well-developed healthcare system, which has made these drugs more accessible to patients.
Underlying macroeconomic factors: The growth of the Immunosuppressants market in Jordan is also influenced by various macroeconomic factors. These include the country's population growth, which has increased demand for healthcare services, as well as the government's focus on improving healthcare infrastructure. Additionally, the country's stable political environment and its strategic location in the Middle East have made it an attractive destination for pharmaceutical companies looking to expand their operations in the region.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
